BRM.HM Bristol-Myers Squibb Company
- Market cap
- -
- P/E
- 14.3x
- P/B
- 5.48x
- ROE
- 46.5%
- Dividend yield
- 1.53%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is BRM.HM undervalued?
Graham numberThe Graham number of Bristol-Myers Squibb Company cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Bristol-Myers Squibb Company fundamental analysis
No fundamental analysis for Bristol-Myers Squibb Company yet.
Bristol-Myers Squibb Company stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Bristol-Myers Squibb Company
There is no Profile data available for BRM.HM.
Full company profileBristol-Myers Squibb Company financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Bristol-Myers Squibb Company annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 19.4B | 20.8B | 22.6B | 26.1B | 42.5B | 46.4B | 46.2B | 45.0B | 48.3B | 48.2B | 50.0B |
| Gross Profit | 14.5B | 14.7B | 16.0B | 18.1B | 30.7B | 36.4B | 36.0B | 34.3B | 34.3B | 34.3B | 35.0B |
| Operating Income | 4.54B | 3.45B | 5.12B | 5.91B | 2.18B | 8.54B | 9.10B | 8.20B | 5.89B | 13.7B | 15.7B |
| EBITDA | - | 6.12B | 6.79B | 7.38B | 4.24B | 18.6B | 19.2B | 19.4B | 3.17B | 15.2B | 17.2B |
| Net Income | 4.46B | 1.01B | 4.92B | 3.44B | -9.02B | 6.99B | 6.33B | 8.03B | -8.95B | 7.05B | 10.9B |
| EPS | - | 0.62 | 3.03 | 1.54 | -4.06 | 3.25 | 3.05 | 3.97 | -4.41 | 3.47 | 5.32 |
| Balance Sheet | |||||||||||
| Total Assets | 33.7B | 33.6B | 35.0B | 130B | 118B | 109B | 96.8B | 95.2B | 92.6B | 90.0B | 88.8B |
| Total Liabilities | 17.4B | 21.7B | 20.9B | 78.2B | 80.6B | 73.3B | 65.7B | 65.7B | 76.2B | 71.5B | 65.4B |
| Shareholders' Equity | 16.2B | 11.7B | 14.0B | 51.6B | 37.8B | 35.9B | 31.1B | 29.4B | 16.3B | 18.5B | 23.4B |
| Cash & Short-term Investments | 4.24B | 5.42B | 6.91B | 12.3B | 14.5B | 14.0B | 9.12B | 11.5B | 10.3B | 10.2B | 9.57B |
| Cash Flow | |||||||||||
| Operating Cash Flow | 2.85B | 5.28B | 5.94B | 8.07B | 14.1B | 16.2B | 13.1B | 13.9B | 15.2B | 14.2B | 11.6B |
| Capital Expenditure | 1.22B | 1.06B | 951M | 836M | 753M | 973M | 1.12B | 1.21B | 1.25B | 1.31B | 1.33B |
| Free Cash Flow | - | 4.22B | 4.99B | 7.23B | 13.3B | 15.2B | 11.9B | 12.7B | 13.9B | 12.8B | 10.2B |
| Ratios | |||||||||||
| ROE | 27.6% | 8.6% | 35.1% | 6.7% | -23.8% | 19.5% | 20.4% | 27.3% | -54.8% | 38.2% | 46.5% |
| ROA | 13.2% | 3.0% | 14.1% | 2.6% | -7.6% | 6.4% | 6.5% | 8.4% | -9.7% | 7.8% | 12.3% |
| Net Profit Margin | 22.9% | 4.8% | 21.8% | 13.2% | -21.2% | 15.1% | 13.7% | 17.8% | -18.5% | 14.6% | 21.7% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Bristol-Myers Squibb Company dividends
- Dividend yield
- 1.53%
- Forward dividend
- -
- Payout ratio
- 71.5%
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | USD 5.05B | 2.48 | 71.5% |
| 2024 | USD 4.86B | 2.40 | - |
| 2023 | USD 4.74B | 2.35 | 59.1% |
| 2022 | USD 4.63B | 2.23 | 73.2% |
| 2021 | USD 4.40B | 2.04 | 62.9% |
| 2020 | USD 4.08B | 1.83 | - |
| 2019 | USD 2.68B | 1.20 | 77.9% |
| 2018 | USD 2.61B | 1.61 | 53.1% |
| 2017 | USD 2.58B | 1.59 | 255.9% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Bristol-Myers Squibb Company
Ownership data of Bristol-Myers Squibb Company is not available yet.
Bristol-Myers Squibb Company company profile
- Company name
- Bristol-Myers Squibb Company
- Ticker
- BRM.HM
- Exchange
- Hamburg Exchange
- Sector
- Other
- Industry
- Metals & Mining
- Fiscal year end
- December
- Address
- Website
- -
About Bristol-Myers Squibb Company
There is no Profile data available for BRM.HM.